OPSEU Pension Plan Trust Fund boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 2.3% during the third quarter, Holdings Channel.com reports. The fund owned 17,370 shares of the company’s stock after acquiring an additional 383 shares during the period. Eli Lilly and accounts for 0.8% of OPSEU Pension Plan Trust Fund’s investment portfolio, making the stock its 13th largest holding. OPSEU Pension Plan Trust Fund’s holdings in Eli Lilly and were worth $2,545,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Nuveen Asset Management LLC grew its position in Eli Lilly and by 42.0% in the second quarter. Nuveen Asset Management LLC now owns 8,026,867 shares of the company’s stock valued at $1,317,851,000 after acquiring an additional 2,372,251 shares in the last quarter. FMR LLC grew its position in shares of Eli Lilly and by 7.0% during the second quarter. FMR LLC now owns 29,992,097 shares of the company’s stock worth $4,924,101,000 after buying an additional 1,954,811 shares in the last quarter. Nordea Investment Management AB grew its position in shares of Eli Lilly and by 96.2% during the second quarter. Nordea Investment Management AB now owns 2,944,184 shares of the company’s stock worth $479,666,000 after buying an additional 1,443,527 shares in the last quarter. Two Sigma Advisers LP grew its position in shares of Eli Lilly and by 72.3% during the second quarter. Two Sigma Advisers LP now owns 2,390,116 shares of the company’s stock worth $392,409,000 after buying an additional 1,003,200 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its position in shares of Eli Lilly and by 60.7% during the second quarter. Robeco Institutional Asset Management B.V. now owns 2,587,159 shares of the company’s stock worth $424,759,000 after buying an additional 977,263 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.
Shares of NYSE LLY traded up $0.59 during midday trading on Tuesday, reaching $141.18. 36,701 shares of the company traded hands, compared to its average volume of 3,963,427. Eli Lilly and Company has a 52 week low of $112.86 and a 52 week high of $170.75. The stock has a 50-day moving average price of $143.73 and a 200 day moving average price of $152.01. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.36 and a quick ratio of 1.06. The company has a market cap of $134.49 billion, a price-to-earnings ratio of 23.13, a PEG ratio of 1.35 and a beta of 0.27.
Eli Lilly and (NYSE:LLY) last released its earnings results on Sunday, November 1st. The company reported $1.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.17). The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.87 billion. Eli Lilly and had a return on equity of 166.45% and a net margin of 24.01%. Eli Lilly and’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.48 earnings per share. As a group, analysts expect that Eli Lilly and Company will post 7.26 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a yield of 2.10%. The ex-dividend date of this dividend is Thursday, November 12th. Eli Lilly and’s payout ratio is currently 49.01%.
In related news, SVP Melissa S. Barnes sold 5,000 shares of Eli Lilly and stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $151.01, for a total value of $755,050.00. Following the transaction, the senior vice president now owns 23,580 shares of the company’s stock, valued at approximately $3,560,815.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.09% of the company’s stock.
A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Berenberg Bank assumed coverage on shares of Eli Lilly and in a report on Tuesday, September 29th. They issued a “hold” rating and a $144.00 price objective for the company. Sanford C. Bernstein assumed coverage on shares of Eli Lilly and in a report on Tuesday, November 10th. They issued a “market perform” rating and a $150.00 price objective for the company. Morgan Stanley decreased their price objective on shares of Eli Lilly and from $176.00 to $170.00 and set an “overweight” rating for the company in a report on Wednesday, October 28th. Finally, ValuEngine downgraded shares of Eli Lilly and from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. One research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $168.07.
Eli Lilly and Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.
Recommended Story: What is a portfolio manager?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.